Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

ANTIMICROBIALS

Targeting viral liquid–liquid phase separation

Liquid–liquid phase separation (LLPS) has recently emerged as a novel mechanism of compartmentalization of biomolecules that form membraneless organelles within cells. Studies have shown that several viral proteins and nucleic acids undergo LLPS to form condensates that support viral replication. Now, two recent studies provide evidence that LLPS during viral replication is a target for antiviral therapy. Risso-Ballester et al. discovered that a steroidal alkaloid cyclopamine and its chemical analogue (A3E) inhibit respiratory syncytial virus (RSV) replication by disorganizing and hardening viral inclusion body (IB) condensates, where viral RNA synthesis occurs. In untreated infected cells, viral IBs had a dynamic nature and the RSV phosphoprotein had a liquid-like behaviour, consistent with the formation of viral IBs through LLPS. In compound-treated cells, IB disorganization occurred within minutes, suggesting that these molecules directly inhibit the liquid properties of RSV IBs. The authors also demonstrated that A3E suppresses viral replication in RSV-infected mice. In a separate study, Wang et al. found that targeting LLPS of the SARS-CoV-2 nucleocapsid protein (NP) with a peptide promotes innate antiviral immunity in vitro and in vivo. Previous work showed that NP phase separates into condensates that contain viral RNA and the viral RNA polymerase. In this study, Wang et al. found that the NP dimerization domain (DD) is required for NP to undergo LLPS with RNA, which prevents Lys63-linked poly-ubiquitination and aggregation of mitochondrial antiviral-signalling protein (MAVS), thus suppressing innate immunity in infection. Using a screening approach, the authors identified a peptide that targets the DD. Remarkably, treatment with the peptide led to the disruption of NP LLPS and increased innate antiviral responses in vitro and in mice. Together, these two studies highlight the potential of targeting LLPS to treat viral infections by disrupting viral replication or boosting host immunity.

References

Original articles

  1. Risso-Ballester, J. et al. A condensate-hardening drug blocks RSV replication in vivo. Nature https://doi.org/10.1038/s41586-021-03703-z (2021)

    Article  PubMed  Google Scholar 

  2. Wang, S. et al. Targeting liquid–liquid phase separation of SARS-CoV-2 nucleocapsid protein promotes innate antiviral immunity by elevating MAVS activity. Nat. Cell Biol. https://doi.org/10.1038/s41556-021-00710-0 (2021)

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Ashley York.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

York, A. Targeting viral liquid–liquid phase separation. Nat Rev Microbiol 19, 550 (2021). https://doi.org/10.1038/s41579-021-00608-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41579-021-00608-6

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing